Literature DB >> 14742216

Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.

James H Jorgensen1, Sharon A Crawford, M Leticia McElmeel, Cynthia G Whitney.   

Abstract

The in vitro activities of two investigational ketolides, cethromycin (formerly ABT-773) and telithromycin, were determined for a selected group of 312 Streptococcus pneumoniae isolates from a national surveillance program. The MIC of cethromycin at which 50% of the isolates were inhibited was 0.008 micro g/ml, and the MIC at which 90% of the isolates were inhibited was 0.06 micro g/ml; the corresponding values for telithromycin were </=0.015 and 0.25 micro g/ml, respectively. For six quinupristin-dalfopristin-resistant strains, the cethromycin MICs were 0.25 to 16 micro g/ml and the telithromycin MICs were 1 to 4 micro g/ml. However, there was only 0.3% resistance to telithromycin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742216      PMCID: PMC321520          DOI: 10.1128/AAC.48.2.605-607.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Authors:  Ross Davidson; Rodrigo Cavalcanti; James L Brunton; Darrin J Bast; Joyce C S de Azavedo; Pamela Kibsey; Christine Fleming; Donald E Low
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Emergence of macrolide resistance during treatment of pneumococcal pneumonia.

Authors:  Daniel M Musher; Mark E Dowell; Virginia D Shortridge; Robert K Flamm; James H Jorgensen; Pierre Le Magueres; Kurt L Krause
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

3.  Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.

Authors:  A M Nilius; M H Bui; L Almer; D Hensey-Rudloff; J Beyer; Z Ma; Y S Or; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens.

Authors:  Angela M Nilius; Dena M Hensey-Rudloff; Megan A Reimann; Robert K Flamm
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

5.  Macrolide resistance among invasive Streptococcus pneumoniae isolates.

Authors:  T B Hyde; K Gay; D S Stephens; D J Vugia; M Pass; S Johnson; N L Barrett; W Schaffner; P R Cieslak; P S Maupin; E R Zell; J H Jorgensen; R R Facklam; C G Whitney
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

6.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.

Authors:  J C Butler; J Hofmann; M S Cetron; J A Elliott; R R Facklam; R F Breiman
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

7.  Detection of erythromycin-resistant determinants by PCR.

Authors:  J Sutcliffe; T Grebe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.

Authors:  John R Lonks; Javier Garau; Lucía Gomez; Mariona Xercavins; Anna Ochoa de Echagüen; Ilana F Gareen; Philip T Reiss; Antone A Medeiros
Journal:  Clin Infect Dis       Date:  2002-08-09       Impact factor: 9.079

9.  In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.

Authors:  Edward O Mason; Linda B Lamberth; Ellen R Wald; John S Bradley; William J Barson; Sheldon L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study.

Authors:  D J Farrell; S Douthwaite; I Morrissey; S Bakker; J Poehlsgaard; L Jakobsen; D Felmingham
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

View more
  8 in total

1.  Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.

Authors:  E Azoulay-Dupuis; J Mohler; J P Bédos; C Barau; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.

Authors:  Marci L English; Christine E Fredericks; Nancy A Milanesio; Nestor Rohowsky; Ze-Qi Xu; Tuah R J Jenta; Michael T Flavin; David A Eiznhamer
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 3.  Ketolides in the treatment of community-acquired respiratory tract infections: A review.

Authors:  Martin S Lipsky
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

4.  Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.

Authors:  George G Zhanel; Christel Johanson; Nancy Laing; Tamiko Hisanaga; Aleksandra Wierzbowski; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  A novel ketolide, RBx 14255, with activity against multidrug-resistant Streptococcus pneumoniae.

Authors:  V Samuel Raj; Tarani Kanta Barman; Vandana Kalia; Kedar Purnapatre; Smita Dube; Ramkumar G; Pragya Bhateja; Tarun Mathur; Tridib Chaira; Dilip J Upadhyay; Yogesh B Surase; R Venkataramanan; Anjan Chakrabarti; Biswajit Das; Pradip K Bhatnagar
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates.

Authors:  Melissa M Daly; Stella Doktor; Robert Flamm; Dee Shortridge
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 7.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30

8.  Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides.

Authors:  Lulla Opatowski; Laura Temime; Emmanuelle Varon; Roland Leclercq; Roland Leclerc; Henri Drugeon; Pierre-Yves Boëlle; Didier Guillemot
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.